

Factsheet

German stock exchange (Xetra)

Marketing document

Investment focus

BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. The target portfolio of BB Biotech will generally consist of 20 to 35 participations. Large positions will be taken in five to eight companies, the top holdings. Together they will account for no more than two-thirds of the portfolio and no single position will have a weighting greater than 25% of portfolio investments. Due to their substantial portfolio weighting, the top holdings should be generating both revenues and income. The portfolio's smaller participations are companies with promising drug candidates in their R&D pipelines. Investments are selected according to a thorough, multi-level due diligence process, with a particular focus placed on the analysis of financial parameters, the respective competitive environment, the development pipeline, the patent portfolio, and end-client perception. ESG factors are taken into consideration while implementing the aforementioned investment objectives.

Facts


Share price	EUR 46.50
Net Asset Value (NAV)	EUR 41.35
Premium/(Discount)	12.5%
Market capitalization	EUR 2'576.1 mn
Investment manager	Bellevue Asset Management AG
AIC sector	Biotechnology
Benchmark (BM)	Nasdaq Biotech Index TR
Foundation	16.11.1993
Fiscal year end	31.12
Financial reports	Quarterly
Bloomberg	BBZA GY Equity
Valor	3838999
ISIN code	CH0038389992
WKN	A0NFN3
Legal structure	Incorporate company
Share type	Registered shares
Share structure	55.4 mn
Management fee	All-in 1.10%
EU SFDR 2019/2088	Article 8

Key figures

Beta	1.23
Correlation	0.92
Volatility	34.2%
Tracking Error	14.49
Active Share	85.06
Sharpe Ratio	0.06
Information Ratio	-0.09
Jensen's Alpha	-2.21

Source: BB Biotech AG, 30.04.2023;
Calculation based on the Net Asset Value (NAV) over the last 3 years.

Indexed performance since launch



Cumulative & annualised performance


Cumulative

	1M	YTD	1Y	3Y	5Y	10Y	ITD	Annualised						
								1Y	3Y	5Y	10Y	ITD		
Share	-7.0%	-13.3%	-15.1%	-5.6%	6.7%	307.3%	1764.2%	-15.1%	-1.9%	1.3%	15.1%	12.2%		
NAV	-1.2%	-10.5%	0.7%	-4.0%	13.9%	199.2%	1560.6%	0.7%	-1.3%	2.6%	11.6%	11.7%		
BM	0.0%	-3.3%	7.4%	8.7%	45.8%	192.0%	1300.9%	7.4%	2.8%	7.8%	11.3%	10.9%		

Annual performance

	2018	2019	2020	2021	2022	YTD
Share	-2.2%	23.4%	18.1%	13.3%	-19.0%	-13.3%
NAV	-11.1%	28.1%	24.8%	-7.8%	-6.7%	-10.5%
BM	-4.3%	27.6%	16.1%	7.4%	-4.5%	-3.3%

Rolling 12-month-performance



Source: BB Biotech AG, 30.04.2023; all figures in EUR %, total return-methodology
Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to the investment company, thus the performance of a benchmark is not a reliable indicator of future performance of BB Biotech it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred.

Top 10 positions

Ionis Pharmaceuticals Inc.		11.9%
Argenx SE		11.5%
Vertex Pharmaceuticals Inc.		10.0%
Neurocrine Biosciences Inc.		9.2%
Moderna Inc		8.0%
Incyte Corp.		7.1%
Intra-Cellular Therapies Inc.		6.1%
Alnylam Pharmaceuticals Inc.		6.0%
Sage Therapeutics Inc		4.6%
Revolution Medicines Inc		3.6%
Total top 10 positions		78.1%
Total positions		28

Sector breakdown

Small Molecule		52.2%
RNA		26.6%
Antibody		17.5%
Gene- and cell therapy		3.7%

Currency breakdown

USD		100.0%
-----	--	--------

Market commentary

In April BB Biotech's share price declined by 9.0% (in CHF) and the Net Asset Value rose by 0.4% (in USD). The Nasdaq Biotech Index was up by 1.5% (in USD) in April.

BB Biotech reported its first quarter result on April 21 showing a net loss of CHF 254 mn, compared to a net loss of CHF 300 mn during the same period of 2022. A small number of portfolio adjustments were made during the first quarter. The Myovant Sumitomo Dainipon Pharma transaction was completed for USD 27 per share of Myovant. In addition, Kezar Life Sciences and Homology Medicines positions were exited. At the end of the quarter, BB Biotech's portfolio comprised 28 positions – concentrated further on profitable companies which now represent more than 1/3 of BB Biotech's portfolio. Well capitalized companies expected to reach sustainable profitability with their current balance sheet constitute more than 40% of the portfolio whereas smaller companies still needing capital make up less than 20% of the portfolio.

Please find below selected highlights from a few of BB Biotech's portfolio companies:

Ionis (-1.0%, in USD) and its partner Biogen announced on April 25 that the FDA has approved QALSODY (tofersen) injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit from ongoing trial(s).

Relay Therapeutics (-31.0%, in USD) announced on April 18 initial clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of P13Ka. The data support initial clinical proof of mechanism, demonstrating that RLY-2608 achieved selective target engagement at multiple predicted efficacious doses with a favorable initial safety and tolerability profile. The data were presented on April 18 at the American Association for Cancer Research Annual Meeting 2023.

Vertex Pharmaceuticals (+8.1%, in USD) and Crispr Therapeutics (+8.2%, in USD) announced April 2 the completion of the rolling Biologics License Applications (BLAs) to the FDA for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The BLAs include requests for Priority Review, which if granted, would shorten the FDA's review of the application to eight months from the time of submission versus a standard review timeline of 12 months.

Outlook

Despite a challenging start to the year, BB Biotech remains focused on value growth and is optimistic about fundamental progress achieved by innovative biotech companies in the large-, mid- and small-cap segments. We continue to believe that these companies are attractive investments; not only due to the currently depressed valuation but also because development, regulatory and commercialization milestones can boost shareholder returns.

Source: BB Biotech AG, 31.03.2023;

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. Where the Sub-Fund is denominated in a currency other than an investor's base currency, changes in the rate of exchange may have an adverse effect on price and income.

Risk and return profile

The investment company's objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.

Target market

The investment company is suitable for retail and professional investors in Switzerland as well as for professional and semi-professional investors in Germany and professional investors in the UK.

Board of Directors

Dr. Erich Hunziker (president)
 Dr. Clive Meanwell
 Dr. Pearl Huang
 Laura Hamill
 Prof. Dr. Mads Krogsgaard Thomsen
 Dr. Thomas von Planta

Investor Relations



Dr. Silvia Siegfried-Schanz
 Investor Relations
 +41 44 267 72 66
 ssc@bellevue.ch



Claude Mikkelsen
 Investor Relations
 +44 7557 048 57
 cmi@bellevue.ch



Maria-Grazia Alderuccio
 Investor Relations
 +41 44 267 67 14
 mga@bellevue.ch

Benefits

- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.

Sustainability Profile – ESG

EU SFDR 2019/2088 product category: Article 8

Exclusions:	ESG Risk Analysis:	Stewardship:
Compliance UNGC, HR, ILO	ESG-Integration	Engagement
Norms-based exclusions		Proxy Voting
Controversial weapons		

Key Figures:

CO ₂ intensity (t CO ₂ /mn USD sales):	28.1 (low)	Coverage:	88%
MSCI ESG Rating (AAA - CCC):	BB	Coverage:	87%

Based on portfolio data as per 30.04.2023; – ESG data base on MSCI ESG Research and are for information purposes only; compliance with global norms according to the principles of UN Global Compact (UNGC), UN Guiding Principles for Business and Human Rights (HR) and standards of International Labor Organisation (ILO); no involvement in controversial weapons; norms-based exclusions based on annual revenue thresholds; ESG Integration: Sustainability risks are considered while performing stock research and portfolio construction; Stewardship: Engagement in an active and constructive dialogue with company representatives on ESG aspects as well as exercising voting rights at general meetings of shareholders. MSCI ESG Rating ranges from "leaders" (AAA-AA), "average" (A, BBB, BB) to "laggards" (B, CCC). The CO₂ intensity expresses MSCI ESG Research's estimate of GHG emissions measured in tons of CO₂ per USD 1 million sales; for further information c.f. www.bellevue.ch/sustainability-at-portfolio-level.

Investment Management Team



Dr. Daniel Koller
 Head Investment Management Team



Dallas Webb
 Investment Management Team



Dr. Christian Koch
 Investment Management Team



Dr. Leonidas Georgiou
 Investment Management Team



Dr. Maurizio Bernasconi
 Investment Management Team



Dr. Stephen Taubenfeld
 Investment Management Team



Dr. Samuel Croset
 Investment Management Team



Felicia Flanigan
 Investment Management Team



Dr. Olivia Woolley
 Investment Management Team



Dr. Can Buldun
 Investment Management Team

Bellevue Asset Management AG is responsible for portfolio management, finance, marketing, sales and administration of BB Biotech AG.



Important information

This marketing document relates to BB Biotech AG (hereinafter the "Company"). As defined under Swiss law, the Company is structured as an holding company with fixed capital (SICAF, cf. Art. 110 ff. of the Swiss Collective Investment Schemes Act, "CISA"), but it is not subject to the CISA due to its listing on the SIX Swiss Exchange, the German Stock Exchange and the Italian Stock Exchange (Art. 2 para. 3 and Art. 110 para. 1c CISA); instead the Company is subject to the supervision of the respective stock exchange authorities. This marketing document is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and which acts as the Investment Manager of the Company.

This communication is issued in the UK by Bellevue Asset Management (UK) Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN: 825152). Consequently, this communication is only made available to professional clients and eligible counterparties as defined by the FCA. The rules made under the Financial Services and Markets Act 2000 for the protection of retail clients may not apply. The Financial Services Compensation Scheme is unlikely to be available.

The prospectus, statutes, the annual and half-yearly reports, share price information and other data about the Company can be obtained free of charge in English and German from the Company, BB Biotech AG, Schwertstrasse 6, CH-8200 Schaffhausen, from the Investment Manager of the Company, Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, or online at www.bbbiotech.ch.

This document is neither directed to, nor intended for distribution to or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. In particular, it is not intended for distribution to any US person within the meaning of Regulation S of the US Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to buy any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information does not take into account the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making an investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as a recommendation or as investment advice.

Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is not an indicator of the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or the investment universe of the Company. The performance of a benchmark is not an indicator of the Company's past or future performance. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and they are only valid on the basis of the latest version of the prospectus and available annual and interim reports. Please take note of the risk factors.

© 2023 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Copyright © 2023 Bellevue Asset Management AG. All rights reserved.